Post-cycle peptide protocols
Most strength peptides don't need PCT. Why peptide cycles aren't like steroid cycles, what HPTA suppression looks like by peptide class, and where PCT fits.
Updated May 7, 2026 · 6 min read
PCT — post-cycle therapy — is a concept imported from anabolic-steroid protocols, where exogenous testosterone suppresses endogenous production and post-cycle drugs (SERMs like Nolvadex or Clomid, sometimes hCG) help restart the HPTA. The whole concept assumes the cycle suppressed the natural hormone-axis enough that recovery requires intervention.
Most strength peptides don't fit that template. They don't suppress the HPTA. They don't shut down endogenous testosterone production. The body's hormone-axis recovery during the off-period happens on its own, without supporting drugs. So the short answer to "do I need PCT after a peptide cycle?" is: usually, no.
This page walks through why, by peptide class, and identifies the narrow cases where something PCT-like might fit.
The core distinction: HPTA suppression
| Compound class | Mechanism | HPTA suppression? |
|---|---|---|
| Anabolic steroids | Exogenous testosterone replaces endogenous signaling | Yes — significant, requires PCT |
| BPC-157, TB-500 | Local angiogenesis, actin reorganization | No |
| Short-acting GH secretagogues | Pulse-style GH release through pituitary | No (pituitary recovers rapidly) |
| Long-acting GH secretagogues | Sustained GHRH/ghrelin elevation | Mild axis modulation, not HPTA suppression |
| IGF-1 LR3 | Direct IGF-1 receptor activation | Brief GH-axis downregulation, recovers naturally |
| MOTS-c, GHK-Cu | Mitochondrial peptide / copper peptide | No |
| MK-677 | Sustained ghrelin-receptor agonism | Mild GH-axis modulation, no HPTA suppression |
Hypothalamic-pituitary-testicular axis (HPTA) suppression is the specific concern PCT addresses for steroid users. None of the strength peptides on this list produce that kind of testosterone suppression.
By peptide class
Recovery peptides (BPC-157, TB-500)
PCT needed: No.
These compounds don't touch the hormone axis. They drive local repair processes. Cycling them is about goal completion and theoretical long-term safety, not about hormone recovery. The off-period is just an off-period. See off-cycle strategies.
Short-acting GH secretagogues (Ipamorelin, CJC-1295 no-DAC, Sermorelin)
PCT needed: No.
These preserve the natural pulsatile GH pattern. The pituitary continues to control release. When you stop, the pituitary keeps doing what it was doing — there's no shutdown to recover from. The off-period is for receptor recovery (mild, if any) and total exposure reduction, not HPTA restart.
Long-acting GH secretagogues (CJC-1295 with DAC, MK-677)
PCT needed: No, but the off-period needs to be longer.
Sustained-elevation forms produce more receptor desensitization than short-acting forms. They also accumulate longer in the body — CJC-1295 DAC has a half-life of about a week. The off-period needs to be long enough for the peptide to clear and for receptors to restore sensitivity. That's not PCT; that's just a longer off-cycle.
IGF-1 LR3
PCT needed: No, but axis recovery takes a few weeks.
IGF-1 LR3 produces brief feedback suppression of the GH axis (elevated IGF-1 signals back to the pituitary to dial down GH release). This recovers naturally during a 4-8 week off-period. No SERMs, no hCG, no aromatase inhibitors. See IGF-1 LR3 protocol and IGF-1 LR3 with GH peptides.
MOTS-c, GHK-Cu
PCT needed: No.
Neither compound modulates the hormone axis. Standard off-period only.
Why this differs so much from steroid PCT
Anabolic steroids work by replacing endogenous testosterone with exogenous testosterone. The body senses high levels of testosterone in circulation and responds by shutting down its own production. When the cycle ends and exogenous levels crash, the body's own production hasn't restarted yet — testosterone is low, sometimes for months. PCT compounds (SERMs, hCG, aromatase inhibitors) speed that restart.
Peptides don't replace anything. GH secretagogues stimulate the pituitary to release more of its own GH; they don't replace the pituitary. BPC-157 doesn't replace any endogenous signal; it adds a separate one. When you stop, there's no exogenous-replacement gap to fill.
The conceptual error is treating "peptide cycle" and "steroid cycle" as the same template. They're not.
Where PCT-like protocols might fit
Three narrow cases where a PCT-style approach can make sense:
| Case | What might fit | Why |
|---|---|---|
| Stack that includes synthetic HGH | Standard HGH off-protocol | HGH cycles do produce more axis suppression than peptide-only cycles. This site does not focus on HGH protocols. |
| Stack that includes anabolic steroids alongside peptides | Standard steroid PCT | The PCT here is for the steroid component, not the peptides. Beyond this site's scope. |
| Long high-dose IGF-1 LR3 runs (uncommon, off-label) | Brief monitoring period before next cycle | More about giving the GH-axis a clear window than running compounds |
If your stack includes synthetic HGH or anabolic steroids, the PCT considerations come from those compounds, not from the peptides — and those protocols are outside this site's scope.
What people often confuse with PCT
Some practices that are sometimes mislabeled as "peptide PCT" but are really just normal cycle hygiene:
| Practice | What it actually is |
|---|---|
| Running an off-period of 4-8 weeks | Standard off-cycle |
| Bloodwork at end of cycle | End-of-cycle reassessment |
| Tapering down a long-acting peptide | Just letting the peptide clear |
| Sleep, nutrition, training adjustments during off | General recovery — applies whether you cycled peptides or not |
| Continuing topical GHK-Cu through the off | Continuous-use peptide, not PCT |
None of these require PCT compounds. They're just what a well-executed off-cycle looks like.
What an end-of-cycle protocol actually looks like
For a typical peptide cycle (recovery stack, GH secretagogue stack, fat-loss stack):
| Step | Timing | Action |
|---|---|---|
| Final injection | Week 12 (or end of cycle) | Standard dose, then stop |
| Bloodwork | Week 14 (2 weeks off) | Comprehensive panel — see off-cycle strategies |
| Subjective documentation | Weeks 1-4 of off | Track sleep, recovery, mood, body comp |
| Reassessment | Week 6-8 of off | Decide on next cycle, alternative protocol, or no cycle |
No PCT compounds. No SERMs. No hCG. Just the off-period.
The "but I read I should run a PCT stack" question
There's a fair amount of internet content that recommends PCT protocols for peptide cycles. Sources of that:
- Cross-application from steroid protocols — same template, different compounds, mostly inappropriate
- Vendor upsells — selling PCT compounds is a separate revenue stream
- Conflation of HGH and peptide cycles — HGH produces more axis effects; peptides don't
- Caution-by-default thinking — "more is safer" reasoning that doesn't track the underlying mechanism
If a protocol you're reading recommends a PCT stack after peptide-only cycles, it's worth checking the mechanism it's addressing. Most of the time, the answer is "the PCT isn't doing what it claims to."